KCM
CLDX icon

Karp Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Karp Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7
Closed -$1K – 128
2015
Q3 		$1K Hold
7
– – ﹤0.01% 337
2015
Q2 		$3K Hold
7
– – ﹤0.01% 337
2015
Q1 		$3K Hold
7
– – ﹤0.01% 319
2014
Q4 		$2K Buy
+7
New +$1.74K ﹤0.01% 332

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Karp Capital Management's CLDX Position: Q4 2015 in Review

Karp Capital Management sold out of Celldex Therapeutics (CLDX) in Q4 2015, closing a stake of 7 shares — an estimated $1K sold.

Karp Capital Management first reported a position in CLDX in Q4 2014 and held it in 4 quarters. The position peaked at $3K in Q2 2015. 171 funds tracked by Wall St. Rank hold CLDX as of Q4 2015.

  • Karp Capital Management reported no remaining Celldex Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Karp Capital Management sold 7 Celldex Therapeutics shares in Q4 2015, an estimated $1K.
  • Karp Capital Management first reported a position in Celldex Therapeutics in Q4 2014 and held it in 4 quarters.
  • Karp Capital Management's Celldex Therapeutics position peaked at $3K in Q2 2015.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2015.

Based on Karp Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.